Elastin-like Polypeptide Mediated Proangiogenic and Anti-inflammatory Gene Therapy for Critical Limb Ischemia
Biraja received his master's degree in Life Sciences in 2005. After working in a research project at IIT Kharagpur, India, he pursued a PhD in Biomaterials in NUI Galway. His work has been supervised by Professor Abhay Pandit and has been conducted in collaboration with the University College Dublin, Elastin Specialities and Queens University, Canada.
Biraja's doctoral research focused on the development of an injectable ELP-based delivery system for proangiogenic and anti-inflammatory gene therapy for critical limb ischemia. ELP based hollow spheres and injectable scaffold were fabricated in order to deliver therapeutic genes such as human eNOS and IL-10. This injectable system has been evaluated in vitro and also in relevant pre-clinical models. During his PhD, he has authored three research articles (Biomaterials, Journal of Controlled Release and Bioconjugate Chemistry) and has been a co-author in one research article and a book chapter. There are three additional first author manuscripts in submission. He has also presented his work at several key conferences.
Prof. Dr. Ivan Martin, following his PhD in Biomedical Engineering at the University of Genova and a postdoctoral training at Harvard/MIT, established in 1999 a Research Group at the University Hospital of Basel. His team includes scientists from the biological, engineering and clinical fields, promoting interdisciplinary, translational work. His research interests are related to mesenchymal cell differentiation and design/implementation of tissue culture bioreactors for automated and controlled manufacturing of cartilage, bone and osteochondral grafts, based on autologous cells and 3D porous scaffolds. He was president of the European section of the Tissue Engineering Regenerative Medicine International Society (TERMIS) and is currently member of the editorial boards of 5 journals. The developed science and technology of the research group have been translated into three clinical trials for cell-based cartilage and bone repair, and into the founding of a spin-out company for the commercialization of tissue culture bioreactors (Cellec Biotek AG).